Compare REGN & SHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | SHW |
|---|---|---|
| Founded | 1988 | 1866 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 81.7B |
| IPO Year | 1995 | 1994 |
| Metric | REGN | SHW |
|---|---|---|
| Price | $746.39 | $319.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $819.54 | $389.15 |
| AVG Volume (30 Days) | 559.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | 0.50% | ★ 1.01% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 41.48 | 10.26 |
| Revenue | $5,872,227,000.00 | ★ $17,900,800,000.00 |
| Revenue This Year | $11.69 | $5.22 |
| Revenue Next Year | $10.06 | $4.59 |
| P/E Ratio | ★ $17.98 | $30.95 |
| Revenue Growth | ★ 20.82 | 2.09 |
| 52 Week Low | $476.49 | $308.84 |
| 52 Week High | $821.11 | $379.65 |
| Indicator | REGN | SHW |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 29.15 |
| Support Level | $740.39 | N/A |
| Resistance Level | $788.69 | $345.06 |
| Average True Range (ATR) | 21.98 | 8.86 |
| MACD | -4.12 | -4.48 |
| Stochastic Oscillator | 6.97 | 4.70 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 4,800 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.